Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Next Previous
Trial Profile

A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durlobactam/sulbactam (Primary) ; Colistin; Imipenem/cilastatin
  • Indications Acinetobacter infections; Bacteraemia; Nosocomial pneumonia; Postoperative infections; Urinary tract infections; Ventilator associated pneumonia; Wound infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ATTACK
  • Sponsors Entasis Therapeutics; ZAI Lab

    • Most Recent Events

    • 27 Feb 2024 According to a ZAI Lab media release, NMPA NDA approval for Sulbactam-durlobactam in infections caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in China expected in 2024.
    • 11 Oct 2023 According to an Innoviva media release, new data from this trial will be presented at IDWeek 2023, October 11-15, held in Boston, MA.
    • 01 Sep 2023 Results reporting efficacy and safety data through 42 days published in The Lancet Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top